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Abstract
Background: Endothelial junctions control functions such as permeability, angiogenesis and contact inhibition.
VE-Cadherin (VECad) is essential for the maintenance of intercellular contacts. In confluent endothelial monolayers,
N-Cadherin (NCad) is mostly expressed on the apical and basal membrane, but in the absence of VECad it localizes
at junctions. Both cadherins are required for vascular development. The intercellular adhesion molecule (ICAM)-2,
also localized at endothelial junctions, is involved in leukocyte recruitment and angiogenesis.
Results: In human umbilical vein endothelial cells (HUVEC), both VECad and NCad were found at nascent cell
contacts of sub-confluent monolayers, but only VECad localized at the mature junctions of confluent monolayers.
Inhibition of ICAM-2 expression by siRNA caused the appearance of small gaps at the junctions and a decrease in
NCad junctional staining in sub-confluent monolayers. Endothelioma lines derived from WT or ICAM-2-deficient
mice (IC2neg) lacked VECad and failed to form junctions, with loss of contact inhibition. Re-expression of full-length
ICAM-2 (IC2 FL) in IC2neg cells restored contact inhibition through recruitment of NCad at the junctions. Mutant
ICAM-2 lacking the binding site for ERM proteins (IC2 ΔERM) or the cytoplasmic tail (IC2 ΔTAIL) failed to restore
junctions. ICAM-2-dependent Rac-1 activation was also decreased in these mutant cell lines. Barrier function,
measured in vitro via transendothelial electrical resistance, was decreased in IC2neg cells, both in resting conditions
and after thrombin stimulation. This was dependent on ICAM-2 signalling to the small GTPase Rac-1, since
transendothelial electrical resistance of IC2neg cells was restored by constitutively active Rac-1.I nv i v o , thrombin-induced
extravasation of FITC-labeled albumin measured by intravital fluorescence microscopy in the mouse cremaster muscle
showed that permeability was increased in ICAM-2-deficient mice compared to controls.
Conclusions: These results indicate that ICAM-2 regulates endothelial barrier function and permeability through a
pathway involving N-Cadherin, ERMs and Rac-1.
Keywords: Endothelial, ICAM-2, N-Cadherin, ERM, Rac-1, Cell adhesion, Permeability, Cell-cell junctions
Lay abstract
Blood vessels are lined by a single layer of cells, called
endothelial cells, which control many critical functions
in the body. Endothelial cells form a tight layer thanks
to the presence of proteins on the surface of the cells,
which bind to similar proteins on neighboring cells.
These proteins, called adhesion molecules, control the
flux of liquid from inside the vessels to the tissue. This
process, called permeability, is essential for the health of
tissues and for the ability of the body to respond to
changes in blood pressure or to inflammation. Control
of this process can be disturbed in diseases such as can-
cer or chronic inflammation. Here we identify a new
mechanism that controls permeability, which is medi-
ated by a protein called ICAM-2. This protein is also im-
portant in regulating inflammation and the formation of
new blood vessels, called angiogenesis. We show that
ICAM-2 regulates the localization of another adhesion
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cell contact (endothelial junctions). This occurs through
signals inside the cells mediated by ICAM-2. These re-
sults could have implications for the regulation of vascu-
lar permeability in particular areas of the body, such as
the eye, and in cancer.
Introduction
Endothelial intercellular junctions play an essential role
in many critical processes, including survival, angiogen-
esis and inflammation [1-3]. A large number of cell
adhesion molecules are localized at the cell junctions;
their extracellular domains support intercellular adhesion
through homophilic and/or heterophilic interactions,
whilst connection to the actin cytoskeleton contributes to
strengthening the intercellular contacts. Complex signal-
ing networks regulated by cell-cell junctions control con-
tact inhibition, cell growth, survival and permeability [2,4].
These pathways are modulated by cross-talk between dif-
ferent junctional adhesion molecules and with other sur-
face receptors.
Cadherins are a large family of Ca
2+-dependent adhe-
sion molecules, which mediate homophilic adhesion
through formation of multimeric complexes at the
adherens junctions (AJ) [5] and are essential for the
maintenance of intercellular contacts. The two main
endothelial cadherins, VE-Cadherin (VECad) and N-
Cadherin (NCad), share similar structures and intracel-
lular binding partners; however they display differences
in tissue distribution and function. VECad expression is
restricted mainly to endothelial cells (EC), whilst NCad
is expressed in several cell types including neurons,
muscle cells and fibroblasts [6-9]. Both cadherins are
involved in vascular development and angiogenesis:
endothelial deletion of either VECad or NCad leads to
embryonic lethality due to vascular defects [10,11].
Whilst the role of VECad in controlling endothelial
junction stability and function has been intensely inves-
tigated, the role of NCad is less clear. In mature stable
vessels, VECad is concentrated at endothelial cell-cell
junctions and is essential for junction stability, whilst
NCad is mainly localized across the cell surface. VECad
has been shown to exclude NCad from mature junc-
tions, through pathways that involve β-catenin and
p120
ctn [12,13] and to negatively regulate NCad levels
[13]. Despite this, some NCad has been reported at
endothelial junctions and shown to be upstream of
VECad during blood vessel morphogenesis [14]. More-
over, in specialized endothelial cells such as corneal
endothelium, NCad is clearly mainly localized at cell-
cell junctions and controls permeability [15].
ICAM-2, a transmembrane glycoprotein of the im-
munoglobulin superfamily expressed by endothelial cells,
platelets and leukocytes [16], is found on the apical surface
of endothelial cells and at cell-cell junctions. Like many
other junctional adhesion proteins, ICAM-2 can sup-
port homophilic adhesion [17,18]. As well as regulating
leukocyte adhesion and transmigration [17,19,20], ICAM-
2 is required for angiogenesis [17]. In addition, ICAM-2
regulates activation of the small GTPase Rac1 in EC [17].
The short intracellular domain of ICAM-2 is linked to the
cytoskeleton through interaction with α-actinin [21] and
with members of the ERM family [22]. The ERM proteins
are implicated in the regulation of cell-cell and cell-matrix
adhesion, partly through the small GTPases pathway (for
review [23]).
In this study we investigate the role of ICAM-2 in
controlling endothelial junctions and barrier function.
We show that ICAM-2 regulates early junction stability
and the transient accumulation of NCad at endothelial
junctions in loosely established contacts. We also show
that ICAM-2 regulates NCad localization through intra-
cellular pathways involving the ERM binding motif and
Rac-1 signalling. Finally, we demonstrate that ICAM-2
controls barrier function and vascular permeability
in vitro and in vivo. Thus we identify a novel connection
in the complex network regulating localization and sig-
naling at endothelial junctions.
Results
Localization of ICAM-2 and NCad on human EC in
sub-confluent vs confluent monolayers
The organization of AJ can be different at different
stages of confluence and maturity; therefore we set out
to investigate the localization of ICAM-2 and the two
cadherins on EC by performing co-staining in HUVEC
monolayers at different stages of confluency. In mono-
layers just beginning to reach confluency (referred to
as “sub-confluent” from now on), both VECad and
NCad showed discontinuous staining at cell-cell contacts
(Figure 1, panel a, b and h); NCad was also distributed
over the apical and basal surface of the cells (Figure 1,
panel a). In confluent monolayers, VECad accumulated
at the junctions to form the characteristic thick zipper-
like structure (Figure 1, panel e and k) whilst NCad was
no longer at cell-cell contacts (Figure 1, panel d) and its
expression levels were downregulated (Additional file 1:
Figure S1). ICAM-2 was localized at cell-cell contacts
and on the apical surface both in sub-confluent and con-
fluent monolayers (Figure 1, panel g and j). These data
indicate that in sub-confluent HUVEC monolayers both
VECad and NCad can be found at the junctions, and
suggest that the localization and expression of N-
cadherin in endothelial cells is partly due to the matur-
ation stage of adherens junctions. ICAM-2 and VECad,
on the other hand, appear to be localized at cell junc-
tions in both sub-confluent and confluent monolayers,
with staining intensity increasing over time.
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is regulated by ICAM-2
To test whether ICAM-2 may be involved in regulating
endothelial junction assembly and/or integrity, we inhib-
ited ICAM-2 expression in HUVEC using ICAM-2
siRNA. This resulted in a significant decrease in ICAM-
2 protein levels (Additional file 2: Figure S2A) and cell
surface staining (Figure 2A, panel d). Morphological
analysis showed that in loosely confluent areas inhibition
of ICAM-2 expression (30 h after siRNA treatment) dis-
rupted the continuity of the early established cell-cell
contacts, with the appearance of gaps (Figure 2A, panel
d-l). Quantification of these areas showed that the num-
ber of junctional gaps in ICAM-2 siRNA-treated cells
was significantly higher compared to cells treated with
control siRNA (Figure 2B). VECad levels were not af-
fected by the loss of ICAM-2 (Figure 2C); VECad junc-
tional staining appeared more fragmented but not
significantly altered by ICAM-2 siRNA treatment (Figure 2A,
panels e and k). On the other hand, in ICAM-2 deficient
cells, NCad localization at the cell junctions of loosely
confluent cells was lost (Figure 2A, panel j) without
modification of NCad level (Figure 2C). Loss of junc-
tional localization was not a generalized phenomenon,
since staining for CD31/PECAM was similar in ICAM-
2 and control siRNA-treated cells (Additional file 3:
Figure S3). These data indicate that ICAM-2 is involved
in regulating NCad localization in recently established
endothelial junctions and is required for junction as-
sembly in primary EC.
ICAM-2 regulates N-Cad localization at cell-cell junction
To investigate whether ICAM-2-dependent signaling is
involved in regulating NCad localization in EC, we gen-
erated ICAM-2 endothelioma lines from WT and
ICAM-2-deficient mice. EC isolated from cardiac tissue
by positive selection [17] were immortalized by infection
with the polyoma virus middle-T oncogene [24]. The
Figure 1 Distribution of ICAM-2, VECad and NCad in sub-confluent vs confluent HUVEC monolayers. Cells were seeded at low confluence
(10000 cells/cm2) and cultured for 24 and 96 hours to achieve sub confluent and confluent endothelial monolayer respectively. For NCad/VECad
co-staining (a-f), NCad was stained using mAb Cl32 anti-NCad followed by anti-mouse AlexaFluor488 (Green) and VECad was stained using mAb
Cl55-7H1 anti-human VECad prelabelled with the Zenon® mouse IgG1 555 kit (Red). For ICAM-2/VECad co-staining (g-l), ICAM-2 was visualized
using mAb BT-1 followed by anti-mouse AlexaFluor 488 (Green) and VECad was stained as described above. Co-staining for ICAM-2 and NCad
was attempted with several antibodies and methods, however due to species incompatibility and the well known limitations of NCad antibodies
available, satisfactory images could not be achieved. Bar = 25 μm.
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firmed by endoglin surface expression (Additional file 4:
Figure S4C) and by functional analysis of tube formation
in matrigel (Additional file 4: Figure S4B). Immortalization
of mouse EC with this approach resulted in loss of VECad
expression (Figure 3D); this allowed us to use these lines
to investigate the function of NCad at the endothelial
junctions. Interestingly, PECAM-1 expression was also
lost in these lines, whilst expression of JAM-A was
retained (data not shown).
The ICAM-2-deficient endothelial line (KOIC2-PmT)
was used for re-expression of murine wild type full
length (IC2 FL) or mutant ICAM-2. After infection of
pBabe-IC2, IC2 FL cells expressed ICAM-2 surface
levels similar to those found in HUVEC (Additional file
4: Figure S4C). In these cells ICAM-2 was strongly local-
ized at cell-cell junctions; intense ICAM-2 staining on
the apical surface of the cells was also observed
(Figure 3E, panel a), as expected [25]. Previous work has
shown that ICAM-2 deficiency in EC result in reduced
tube formation in Matrigel [17]. Tube network formation
was restored in IC2 FL cells, compared to IC2 neg cells
(Additional file 4: Figure S4B), indicating that the pheno-
type of the IC2 neg cells can be reversed by re-expression
of ICAM-2.
A striking difference in cell morphology between IC2
neg and IC2 FL mouse cell lines was observed. IC2
neg cells were unable to form a confluent cobblestone
monolayer; organized junctions between cells were lost
and the cells grew on top of each other, suggesting loss
of contact inhibition (Figure 3A, panel a). Cobblestone
morphology and junction formation were restored
by over-expression of ICAM-2 in the IC2 FL cells
(Figure 3A panel b). To test whether the disruption of
the monolayer resulted in disruption of cell growth, we
measured the proliferation rate of the two endothelial
Figure 2 Distribution of NCad in early endothelial cell-cell junctions is regulated by ICAM-2. A- Distribution of ICAM-2, VECad and NCad in
HUVEC ~30 hours post siRNA treatment (a-i: control siRNA; d-l: ICAM-2 siRNA). Arrows indicate the gaps between cells that transiently appeared
following ICAM-2 inhibition by siRNA. For ICAM-2/VECad co-staining (a-f), see details in Figure 1 legend. Bar = 25 μm B- Quantification of the
number of gaps. The gaps were counted manually from 15 fields taken from confocal immunofluorescence images (233 μm x 233 μm, see panel
B) in two independent experiments. Results are shown as % of gaps per number of cells per field. Error bars indicate mean ± S.E.M., n = 30.
Statistical analysis (t-test: ***p < 0.001). C- VECad and NCad levels are unchanged 30 h post-treatment with ICAM2 siRNA. Quantification of VECad
and NCad: Western blot quantification was performed by densitometry, normalized to α-tubulin. Error bars indicate mean ± s.e.m., n = 5.
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of IC2 neg (a), IC2FL (b), IC2 ΔERM (c) and IC2 ΔTAIL (d) cells. Bar = 150 μm. B- Analysis of ICAM-2 surface protein expression by FACS in IC2 neg
(a), IC2 FL (b), IC2 ΔERM (c), IC2 ΔTAIL (d) cells; below, diagram showing the WT and mutant sequences of the constructs. FACS staining was
performed using mAb 3C4 anti-mouse ICAM-2. C- Growth curves of MCEC cell lines. IC2 neg, IC2 ΔERM and IC2 ΔTAIL cells show loss of contact
inhibition of cell growth. Results are represented as number of cells/cm
2 over time (hours). D- Western blot analysis of NCad and VECad levels in
IC2 neg, IC2 FL, IC2 ΔERM and IC2 ΔTAIL endothelioma lines and heart tissue from WT and IC2 deficient mice (ko). VECad and NCad were
detected using mAb BV13 and mAb Cl32, respectively. Error bars indicate mean ± s.e.m., n = 3. E- Analysis of ICAM-2 and NCad distribution in
IC2 FL (a-c), IC2 neg (d-f), IC2 ΔERM (g-i) and IC2 ΔTAIL (j-l) cells. ICAM-2 was stained with mAb 3C4 anti-mouse ICAM-2 followed by anti-rat
AlexaFluor488 (Green). NCad was stained with mAb Cl32 anti-NCad followed by anti-mouse AlexaFluor555 (Red). Nuclei were stained using
TOPRO-3 (Purple). Bar = 25 μm. F- Inhibition of NCad expression in IC2 FL cell line by siRNA resulted in disruption of cell-cell contacts and
altered cell morphology. (a)- Phase contrast image of scrambled siRNA (a) and NCad siRNA (b) 48 hours post-transfection, Bar = 150 μm.
(b)- Localization of ICAM-2 and NCad in IC2 FL cells treated with 48 hours scrambled (a-c) or NCad siRNA (d-f).
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FL cells reached a plateau at 72 hours, whilst IC2neg
cells continued to proliferate. These findings indicate
loss of contact-dependent inhibition of cell growth in
IC2 neg cells. In these cells, VECad disappears after
immortalization ([26] and Figure 3D), whilst NCad is
expressed at high levels. NCad protein levels were simi-
lar in both lines (Figure 3D). NCad staining was dif-
fusely expressed on the cell surface of IC2 neg cell line
(Figure 3E, panel e); however, when ICAM-2 expression
w a sr e s t o r e d( I C 2F L ) ,N C a dw a sr e c r u i t e dt ot h ej u n c -
tions (Figure 3E, panel b).
To test whether NCad was responsible for junction as-
sembly and contact inhibition of cell growth in these
cells, NCad expression was inhibited in the IC2 FL line
using siRNA (Figure 3F and S2B). Inhibition of NCad
expression in IC2 FL cells resulted in loss of normal
cobblestone appearance (Figure 3F, panel b). The cells
showed irregular morphology and loss of contact inhib-
ition; ICAM-2 staining was distributed on the apical sur-
face and in some areas around the edge of the cells
(Figure 3F, panel b). Thus, in the absence of VECad,
NCad localizes at cell-cell junctions, where it regulated
contact inhibition and junction assembly. ICAM-2 is
required for NCad localization at the junctions; defi-
ciency of ICAM-2 results in loss of NCad junctional
localization and, in the absence of VECad, loss of con-
tact inhibition and junction assembly.
ERMs are involved in the ICAM-2-dependent N-cadherin
recruitment and junction formation
ICAM-2 regulates several signal transduction pathways.
Ligation of ICAM-2 in leukocyte and fibroblast lines re-
sulted in activation of the PI-3K/Akt pathway and inhib-
ition of apoptosis, through involvement of ERM proteins
[27]. To test whether ICAM-2 intracellular signaling and
interaction with ERM proteins are involved in recruit-
ment of NCad to the junctions, we generated two
ICAM-2 mutants, one lacking the 28 amino acids (aa
249-277) corresponding to the cytoplasmic tail (IC2
ΔTAIL), and one where the ERM binding site (residues
255 to 264, RxxTYxVxxA) was mutated (IC2 ΔERM). To
abolish ERM binding without affecting the α-actinin
binding site, only the first three key residues R, T and
Y of the ERM binding motif were mutated to alanines
(Figure 3B). Individual loss of these residues has previ-
ously been shown to abrogate interaction between
ICAM-2 and ERMs [28]. The mutant ICAM-2 cDNAs
were cloned into pBabe retroviral vectors and used to infect
the IC2 neg-PmT endothelioma line (see above). Surface
expression levels of ICAM-2 in the IC2 FL, IC2 ΔERM and
IC2 ΔTAIL lines were similar (Figure 3B). When examined
by phase contrast microscopy (Figure 3A), IC2 ΔERM and
IC2 ΔTAIL cells were unable to form cobblestone
monolayers, similar to IC2 neg cells. Both IC2 ΔERM and
IC2 ΔTAIL cells showed an irregular and elongated morph-
ology with projections often protruding over neighboring
cells; this was more pronounced in the IC2 ΔTAIL mutant
line (Figure 3A and 3E, panel g and j). Proliferation curves
of both mutant cell lines resembled that of the IC2 neg
cells, with exponential growth and no plateau (Figure 3C),
indicating loss of contact inhibition. We next investigated
the cellular localization of ICAM-2 and NCad in the cell
lines. In IC2 ΔERM and IC2 ΔTAIL cells, ICAM-2 was
diffusely expressed over the apical surface and on the ir-
regular cytoplasmic projections (Figure 3E). In both
mutant lines, NCad was also diffusely expressed on the
cell surface, similar to the pattern observed in the IC2
neg line (Figure 3E). Co-localization of NCad and
ICAM-2 is clearly visible in areas of cell-cell contact.
Expression levels of NCad were comparable across all
IC2 lines (Figure 3D). These results indicate that
ICAM-2 localization at the junctions is dependent on
its cytoplasmic tail and on the interaction with ERM
proteins. Moreover, NCad localization and junction
assembly in these cells requires intracellular signaling
through ICAM-2 and ERMs.
ICAM-2 interaction with ERM proteins regulates Rac1
activity
Rac1 is key regulator of the actin cytoskeleton, cell mo-
tility, junction assembly and stability and can modulate
assembly and disassembly of adherens junctions [28-32].
We have previously shown that ICAM-2 cross-linking in
EC results in increased activation of the small GTPase
Rac1, and that Rac1 activity is decreased in ICAM-2 de-
ficient cells [17]. As expected, IC2 neg cells showed de-
creased levels of Rac1 activity compared to IC2 FL cells
(Figure 4A). To determine whether the activation of
Rac1 by ICAM-2 is dependent on ICAM-2 binding to
ERMs, we measured Rac1 activity in the IC2 ΔERM and
IC2 ΔTAIL cell lines. In both cell lines Rac1 activity was
decreased compared to IC2 FL (Figure 4A). These data
indicates that ICAM-2 mediates activation of Rac1 in
EC via a signaling pathway involving ERMs.
Rac1 is involved in ICAM-2-dependent recruitment of
NCad and junction assembly
Rac1 activity is required to assemble adherens junctions,
in a complex and dynamic pathway. To establish
whether Rac1 is involved in the ICAM-2 and NCad-
dependent regulation of endothelial junction stability, we
made use of two well characterized mutants of Rac1,
V12-N17 and V12, which are respectively a dominant
negative (DN) and a constitutively active form (CA) of
Rac1 [33]. IC2 neg and IC2 FL cells were transfected
with plasmids expressing DN Rac1-GFP or CA Rac1-
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as controls. Similar expression levels were obtained in
each cell type (data not shown). In IC2 neg cells, over-
expression of CA Rac1-GFP, but not DN Rac1-GFP or
GFP alone, resulted in restoration of junctions and
cobblestone morphology (Figure 4 B, panels a-l). CA
Rac1-GFP was concentrated at the cell-cell contacts, as
expected [34] (Figure 4 B, panel g). In contrast, disrup-
tion of Rac1 activity in IC2 FL cells by DN Rac1-GFP re-
sulted in loss of the regular cobblestone appearance and
of cell-cell contacts (Figure 4 B, panels m-x). Over ex-
pression of CA Rac1 or GFP alone in IC2 FL cells did
not affect the cobblestone appearance (Figure 4B, panels
s and o, respectively). In line with these findings, NCad
junctional staining, normally absent in IC2 neg cells
(see Figure 3E), was restored by over-expression of CA
Rac1-GFP (Figure 4B, panel f), but not by DN Rac1-GFP
(Figure 4B, panel j). These results indicate that ICAM-2
activation of Rac1 is involved in NCad localization and
endothelial junction formation.
ICAM-2 is controls barrier function and vascular
permeability
The results shown so far indicate a role for ICAM-2 in
regulating endothelial junction stability and the recruit-
ment of NCad. To test whether ICAM-2 controls endo-
thelial barrier function, we measured transendothelial
electrical resistance (TEER) by impedance spectroscopy
in IC2 neg and IC2 FL lines. Baseline TEER was signifi-
cantly higher in IC2FL cells compared to IC2 neg cells
(Figure 5A). Thrombin treatment induced a reduction of
TEER in all endothelioma cell lines but barrier break-
down was significantly stronger in IC2 neg than IC2 FL
cells (Figure 5B) indicating that the baseline endothelial
barrier was weaker and also that the barrier was more
susceptible to permeabilising agents in the absence of
ICAM-2. Rac1 has been shown to control endothelial
permeability [35,36]. To determine whether Rac1 was in-
volved in ICAM-2-dependent barrier regulation, we ana-
lyse the transendothelial electrical resistance in IC2 neg
and IC2 FL cells, infected with recombinant adenovirus
expressing constitutively active (DA) or dominant nega-
tive Rac1 (DN). In IC2neg cells, DA Rac1 restored the
transendothelial electrical resistance to a level similar to
IC2 FL, whilst DN had no effect. On the other hand, DN
Rac significantly decreased the transendothelial electrical
resistance in IC2 FL, whilst DA had no effect (Figure 5C).
Finally, we tested the role of IC2 in regulating vascular
permeability in vivo, by measuring the extravasation of
FITC-labeled albumin via intravital fluorescence micros-
copy in postcapillary venules of the mouse cremaster
muscle. Thrombin caused an increase in FITC-labeled al-
bumin into the adjacent tissue. This effect was signifi-
cantly enhanced in mice lacking IC2 vs. WT counterparts
(Figure 5D) suggesting that the absence of ICAM-2 in-
creases vascular permeability. Taken together these data
indicated that the absence of ICAM-2 in vitro or in vivo
increases vascular permeability.
Discussion
In this study, we present new evidence that the adhesion
molecule ICAM-2 is involved in junction stability and
the control of permeability by recruiting NCad to the
junctions, through pathways which involve ERM pro-
teins and the small GTPase Rac1.
Staining for ICAM-2, NCad and VECad in sub-
confluent and confluent HUVEC suggests that NCad
junctional localization is transient and occurs at the
early stages of cell-cell contact. VECad has been shown
to displace NCad from the junctions [12,37,38] and
NCad levels are downregulated at confluence [39]. In-
hibition of ICAM-2 expression in HUVEC by siRNA re-
sulted in a transient loss of cell-cell contacts and
displacement of NCad from the junctions. The transient
nature of the disruption of cell junctions caused by
ICAM-2 siRNA is likely due to the recruitment and en-
gagement of VECad at the junctions, which over-rides
NCad in maintaining junction stability and is seemingly
independent of ICAM-2. Therefore we made use of en-
dothelioma mouse lines where VECad expression was
permanently lost, to study the role of NCad at the junc-
tions and the role of ICAM2 in regulating its function.
The absence of VECad expression from mouse endothe-
lioma lines has not been reported consistently. Loss of
VECad expression in endothelioma lines has been ob-
served before [26]; however, endothelioma lines from
WT, ICAM-2 or ICAM-1/ICAM-2 double deficient mice
were found to express VE-Cad [40,41]. The reason for
(See figure on previous page.)
Figure 4 ERMs and Rac1 activity are involved in ICAM-2-dependent NCad recruitment and cell-cell contact. A- Rac1 activity in MCEC cell
lines, as measured by the GST-PAK pull-down assay. (a) Representative Western blot analysis of Rac1 activity. Rac1-GTP pull-down with GST-PAK
as well as total Rac1 were detected using mAb Cl23A8. (b) Quantification of Rac1 activity (Rac1-GTP/Total Rac1) in IC2 neg, IC2 FL, IC2 ΔERM,
IC2 ΔTAIL cell lines. Error bars indicate mean ± s.e.m., n = 6. Statistical analysis (t-test: *p < 0.05, **p < 0.005). B- Effect of DN and CA Rac1 on the
morphology and the distribution of NCad in the IC2 neg and IC2 FL lines. IC2 neg or IC2 FL were transfected with pEGFP control (a-d and m-p),
pEGFP-V12 Rac1 (e-h and q-t) or pEGFP-V12-N17 Rac1 (i-l and u-x). Cells were co-stained for ICAM-2 and NCad. ICAM-2 was stained using the
mAb 3C4 anti-mouse ICAM-2 followed by anti-rat AlexaFluor488 (pseudo colored Red). NCad was stained using mAb Cl32 anti-NCad followed by
anti-mouse AlexaFluor555 (pseudo colored Blue). Bar = 25 μm.
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ferent protocols for immortalization may be responsible
for these differences. Alternatively, or perhaps in com-
bination, the tissue of origin of the cells might influence
the ability of the endothelioma lines to retain certain ex-
pression profiles. However, in our hands lines from both
heart and lung lost VECad expression after passaging.
Moreover, three different preparations of endothelioma
lines were established and investigated, and all showed
the same adhesion molecules’ profile (data not shown).
In non-endothelial tissues, NCad is concentrated at
cell-cell contacts where it plays an important role in
maintaining barrier function; however the role of NCad
at endothelial cell-cell contacts is poorly understood.
Several reports show NCad expression in confluent EC
monolayers to be diffusely distributed over the surface
rather than junctional [37,42]. However, in line with our
findings, others have identified NCad expression at
endothelial cell-cell junctions and have suggested an in-
direct role for NCad in regulating junction assembly and
stability [14], possibly through the control of VECad ex-
pression. The data presented here suggests that NCad
may also play a direct, VECad-independent role in main-
taining the integrity of immature junctions.
Our data suggest that NCad may be present at imma-
ture AJ, possibly during vascular remodeling and/or
angiogenesis, or inflammation. AJ organization is differ-
ent at different stages of cell confluency [43]. Thus, our
findings may have implications for neo-vascularization.
NCad expression has been associated with neo-vessels in
the context of dental inflammation, where the gener-
ation of new vessels, in response to dental pulp inflam-
mation, is accompanied by re-expression of NCad in
endothelial cells [44]. In tumor angiogenesis, the fre-
quency of hypervascular tumours was shown to be sig-
nificantly higher for NCad-positive carcinomas than for
NCad-negative carcinomas [45]. A direct role for NCad
in angiogenesis has been show by Derycke et al, who
demonstrated that soluble NCad promotes angiogenesis
in both in vitro and in vivo models [46].
Figure 5 In vitro and in vivo cell permeability assays. A- Cells were grown in full medium on gold electrodes until stable impedance was
reached. TEER changes were recorded after 48 h and changes in TEER at baseline or B- after 10 min thrombin stimulation. Shown are average values
-/+ s.e.m. of 4 independent experiments. C- Cells were grown in full medium on gold electrodes until stable impedance was reached. Cells were then
infected with recombinant adenovirus encoding constitutively active (DA) or dominant negative (DN) myc-Rac1 at an m.o.i. of 400. After 4 h the virus
was removed and cells starved to assess barrier development. TEER changes were recorded after 48 h. Shown are average values -/+ s.e.m of 4
independent experiments. D- In vivo permeability assay: albumin leakage in postcapillary venules from the cremaster muscles of WT and ICAM-2 KO
(IC2 neg) mice in response to thrombin (2U/mL) during 10 min. Data are mean ± s.e.m. of n = 6 mice per group. t-test WT vs IC2-/- *p <0 . 0 5 ,
**p < 0.01.
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cialized types of endothelium, such as corneal endothe-
lium (CE). In CE, NCad is a differentiation marker since
its expression coincides with the formation of the endo-
thelial cell layer during eye development [15]. Also, in
CE the anti-inflammatory neuropeptide VIP up-regulates
NCad expression [47]. In the eye, NCad has been shown
to regulate vascular permeability [15]. NCad deficiency
resulted in disorganization of apical junctional complex
in CE, and fluorescein dye injection in the anterior
chamber demonstrated increased permeability of the
endothelium and corneal edema. To our knowledge, the
expression and function of ICAM-2 in CE has not yet
been investigated.
In this paper we show that ICAM-2 regulates
localization of NCad at the junctions via a pathway in-
volving ERM proteins and the small GTPase Rac1.
Over-expression of constitutively active Rac1 restored
cell-cell contacts and NCad junctional localization in
ICAM-2 deficient cells, and conversely inhibition of
Rac1 activity in ICAM-2 over-expressing cells results in
monolayer disruption, suggesting that ICAM-2 mediates
junction assembly, at least in part, via the Rac1 pathway.
Several junctional molecules, including cadherins, have
been implicated in Rac1 activation [29,48,49]. The inter-
play between different stimuli could be critical for time-
dependent regulation of Rac1 activation and remains to
be investigated. Our data shows that interaction with
ERM proteins is required for the ICAM-2-dependent re-
cruitment of NCad at the junctions and contact inhib-
ition of cell proliferation, as well as ICAM-2-dependent
activation of Rac1.
ICAM-2, like many other adhesion molecules, is
known to play multiple roles in EC: leukocyte trafficking,
inflammation and angiogenesis. These data now add a
novel function, namely regulation of permeability. These
findings may be particularly relevant to inflammation. In
the ICAM-2 KO mice, thrombin-induced permeability
was reduced compared to controls. Thrombin is known
to have a significant remodelling effect over endothelial
junctions, by acting through several pathways including
small GTPases for review [36]. Our data suggests that
ICAM-2 controls the cellular response to thrombin by
regulating Rac1 activity. Future studies will investigate
the role of ICAM-2 in permeability induced by other
stimuli, and the possible cross-talk with other cell sur-
face receptors in controlling barrier function.
Conclusions
In conclusion, the data presented here describe a new
role for the adhesion molecule ICAM-2 in regulating the
localization of NCad in the early stages of monolayer
formation and in the control of permeability. Based on
these results, we propose a model where ICAM-2
supports early contact between EC by driving recruit-
ment of NCad at the junctions. This model is similar to
that proposed for nectins, cell adhesion molecules of the
Ig superfamily which regulate the organization of adhe-
rens junctions by mediating early contact between epi-
thelial cells and recruiting E-Cadherin to the junctions
[50]. Because of the role of NCad in new vessel forma-
tion, these results suggest ICAM-2 might regulate per-
meability and angiogenesis at least in part through its
ability to recruit NCad at the junctions.
Methods
Animals
All animal care and experimental procedures were per-
formed under licence and complied with the UK Ani-
mals (Scientific Procedures) Act, 1986. ICAM-2
deficient mice [40] where backcrossed for 10 generations
with C57/BL6 WT mice, supplied by Charles River La-
boratories UK. WT and ICAM-2 deficient mice were 8-
11 months old at the time of the experiments. Animals
were maintained in standard condition at the Biological
services Unit, Hammersmith Hospital, London, UK.
Reagents and antibodies
Antibodies (Ab) against human ICAM-2, monoclonal
Ab (mAb) BT-1 and polyclonal sc-1512, were obtained
from Serotec and Santa-Cruz, respectively. mAb against
mouse ICAM-2 (3C4) was obtained from Pharmingen.
mAb against NCad (Cl 32) was purchased from BD Bio-
science. mAbs against human VECad were purchased
from BD bioscience (Cl75) and Pharmingen (Cl55-7H1).
The mAb anti-mouse VECad (BV13) was kindly pro-
vided by Prof Elisabetta. Dejana (IFOM, Italy [51]). mAb
PECAM-1 P2B1 was purchased from Santa-Cruz. mAb
MJ7/18 anti-mouse endoglin was purchased from Che-
micon. mAb Cl 23A8 anti-Rac1 was purchased from
Transduction Laboratories. The anti-α-tubulin was ob-
tained from SIGMA. The pBabe-Puro retroviral vector
was a gift from Dr Aleksandar Ivetic (King’s College
London, UK). PEGFP-C1 control, constitutive active V12
Rac1-GFP and dominant negative V12-N17 Rac1-GFP
were kindly provided by Prof. Francisco Sanchez-Madrid
(Universidad Autonoma de Madrid, Spain [33]. The
PAK-GST construct was kindly provided by Prof. Anne
Ridley (King’s College London, UK). Fluroscein isothio-
cyanate (FITC)-labelled albumin (Sigma, UK) solubilised
in deionised water. Thrombin was purchased from
Sigma-Aldrich (Poole, Dorset, UK) and solubilised in
physiological saline.
Generation and culture of mouse endothelioma lines
Primary murine cardiac endothelial cells (MCEC) were
isolated from ICAM-2 deficient mice as previously de-
scribed [52]. The released EC were isolated by positive
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nyi Biotech). MCEC cells were cultured in DMEM sup-
plemented with 10% fetal calf serum (FCS), 30ug/mL
endothelial cell growth supplement (ECGS; BD Biosci-
ences), 10 U/mL heparin, 2 mM L-glutamine, 100 IU/mL
penicillin, and 0.1 mg/mL streptomycin). For all experi-
mental assays, the cells were grown in DMEM media sup-
plemented with 1% FCS.
Immortalization of primary MCEC cells was carried out
with Polyoma middle T oncogene known to immortalize
only the endothelial cells [24]. To generate cell lines ex-
pressing full length or mutant murine ICAM-2, the im-
mortalized MCEC IC2 negative line was infected with the
retroviral supernatant corresponding to the empty vector
pBabe-Puro, pBabe-IC2, pBabe-IC2 ΔTAIL or pBabe-IC2
ΔERM at a multiplicity of infection of 0.025 to generate
the following lines: IC2 neg, IC2 FL, IC2 ΔERM and IC2
ΔTAIL, respectively. Plasmids contruct methods were
detailed in additional data section. Retroviral supernatants
were generated by transfecting Phoenix ecotropic pack-
aging cells (Orbigen Inc) with calcium phosphate ac-
cording to the manufacturer’sp r o t o c o l .9 6h o u r s
post-infection, cells were selected with puromycin (5
μg/mL, SIGMA). All the MCEC cells lines are poly-
clonal populations, thereby excluding a possible influ-
ence of vector integration on the phenotype.
Transfection endothelioma cell lines
Endothelioma cell lines IC2 neg and IC2 FL were trans-
fected with the plasmid pEGFP-C1 control, constitutive
active Rac1 pEGFP-V12 or constitutive negative Rac1
pEGFP-V12-N17 with Lipofectamine2000 (Life tech-
nologies), according to the manufacturer’s procedure.
To generate cell line, KOIC2-PmT cells were infected
with the retroviral supernatant pBabe-IC2 encoding full-
length (FL) mouse ICAM-2 (IC2 FL), or empty vector
pBabe (IC2 neg).
Isolation and culture of HUVEC
HUVEC were isolated as previously described [53]. The
use of human EC was approved by Hammersmith
Hospital Research Ethics Committee (06/Q0406/21).
Inhibition of expression by RNA interference
Human ICAM-2 siRNA (20 nM, Dharmacon) were de-
livered into 30% confluent HUVEC, cultured in EGM-2
media (Lonza-Cambrex) using AtuFECT01 lipid (1 μg/mL;
Silence Therapeutics, Berlin, Germany) [54]. Non-targeting
siRNA (Dharmacon) at the same concentration was used
as a control. The following day, the transfection complex
was replaced with medium M199 (containing 10% FCS
and 15 μg/mL ECGS). After 6 hr, this was replaced with
medium M199 (containing 10% FCS and 7.5 μg/mL ECGS)
until analysis. Inhibition of NCad expression in IC2 FL was
performed in medium DMEM 1% FCS using the same
methods and siRNA concentration that was used for
HUVEC. The siRNA sequences used were: NCad siRNA
(UGUCAAUGGGGUUCUCCACdTdT) and GUGGAGA




Endothelial barrier assessment: Cells were grown on
gold electrodes (in 8W1E arrays) and transendothelial
electrical resistance (TEER) measured by real time im-
pedance spectroscopy using ECIS (Applied Biophysics).
Cells were grown to confluence in full medium and then
switched into starvation medium containing 1% FCS for
48 h at which point TEER values were recorded. To as-
sess responsiveness to vasoactive treatment, starved cells
were stimulated with 1 U/ml thrombin (Sigma) and
TEER changes measured after 10 min. To assess the role
of Rac1, cells were infected with recombinant adenovi-
ruses encoding constitutively active (V12) or dominant-
negative (N17) myc-tagged Rac 1 [35] (a kind gift from
Prof Anne Ridley, King’s College London, UK) at an
m.o.i. of 400. After 4 h, virus was removed and the
cells switched to starvation medium to assess barrier
development.
In vivo permeability assay: Vascular permeability assay
in-vivo was performed using the technique of measuring
plasma protein extravasation in the mouse cremaster
muscle [55]. Briefly, mice (WT and ICAM-2 deficient
mice) were anaesthetised with ketamine (150 mg/kg;
Ketaset, Fort Dodge Animal Health, Southampton, UK)
and xylazine (7.5 mg/kg; Rompun, Bayer Healthcare,
Newbury, UK). The jugular vein was exposed and can-
nulated with polyethylene tubing (PE10) for drug/dye
administration.
The cremaster muscle was exteriorised [55,56] and
gently laid across a Plexiglass viewing stage; and
mounted on an Olympus “BW61WI” microscope with a
water-immersion objective lens (magnification of 40×;
LUMPlan, FI/IR, Olympus, Japan). Vascular permeability
was measured by injecting FITC-albumin i.v. (0.25 mg
per gram body weight) 10 min before recording. Five mi-
nutes prior to recording, thrombin (2 U/ml) was admin-
istered i.v. A snapshot of vessel fluorescence was taken
using a block filter (excitation at 450—490 nm, emission
at 535—620 nm) and a camera (model CoolSNAP HQ
2,
Photometrics, Tucson, AZ) coupled to a Windows
XP-based computer for recording by Slidebook 4.2 (In-
telligent Imaging Innovations, Inc., Denver, CO). Post-
capillary venules with diameters of 20-40 μmw e r e
analyzed for a period of 10 minutes. Albumin leakage
was quantified by measuring mean fluorescence inten-
sity using ImageJ64 (National Institute of Health, USA).
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size was measured: inside the vessel (Flin), outside the
vessel (Flout) and background fluorescence in an area
with no obvious leakage (bk). Albumin leakage was then
determined as: [(Flout × bk)/(Flin × bk)] × 100%.
Flow cytometry (FACS)
FACS analysis was performed using standard methods
[52] and analyzed on an Epic XL-MCL flow (Beckman-
Coulter).
Cell proliferation assay
Cells were seeded onto 1% gelatin-coated 24 wells plates
at 2500 cells/cm
2, and counted using a hemocytometer
in triplicate every day over 4 days.
Western blot
Total protein was extracted using RIPA lysis buffer
(10 mM sodium phosphate pH 8, 150 mM NaCl, 1% so-
dium deoxycholate, 1% NP40, 0.5% SDS, 1 mM PMSF,
10 mM NaF, 1 mM sodium orthovanadate) and protease
inhibitor cocktail (SIGMA). Protein extracts were ana-
lysed by SDS-PAGE followed by immunoblotting using
the indicated antibodies and detected using an enhanced
ECL detection system (GE Healthcare). The intensity of
the bands was quantified using alpha Innotech Chemi
Imager software.
Immunofluorescence microscopy
Cells were cultured on glass cover-slips, fixed with 4%
paraformaldehyde, permeabilized with 0.4% Triton-X100
and immunostained with the indicated primary antibodies.
Subsequent visualization was performed with AlexaFluor-
conjugated Ab (Life technologies). For ICAM-2/VECad or
VECad/NCad co-staining, VECad was labeled using the
ZENON® kit (Life technologies), according to the manufac-
turer’s protocol. Nuclei were visualized using TOPRO-3
(Life technologies). Images were captured with a confocal
microscope (LSM510 META; Carl Zeiss). Adobe Photo-
shop was used according to the guidelines to construct the
confocal multi-channel images, to select specific regions of
interest and to apply minor alterations to contrast and
brightness uniformly across the entire figure panel.
Rac pull-down assay
Rac1 activity was determined as previously described
[17]. Briefly, cells were grown in reduced media for
48 hours and lysed in magnesium lysis buffer 1× (MLB)
on ice. GTP loading of Rac was measured using 100 μg
GST-PAK bound to glutathione beads (GE Healthcare),
as previously described [57]. The detailed protocol of
the Rac pull-down assay and preparation of lysis/wash
buffers was provided by Upstate Biotechnology (Rac
activity Assay kit).
Statistics
Data are expressed as mean ± s.e.m. Comparisons be-
tween groups were performed with a two-tailed t-test
using Prism software (GraphPad, San Diego, CA, USA).
Additional files
Additional file 1: Figure S1. Analysis of N-Cad levels in confluent and
sub-confluent HUVECs. N-Cad levels were measured by Western-Blot in
HUVECs at 48h post-seeding, in sparse (5000 cells/cm2) and confluent
condition (500000 cells/cm2). Quantification was performed by densitometry,
normalized with GAPDH. Error bars indicate mean ± s.e.m., n=3. t-test sparse
vs confluent *p<0.05.
Additional file 2: Figure S2. Analysis of ICAM-2 and N-Cad level after
siRNA treatment. A- Analysis by Western-blot of ICAM-2 level after IC2
siRNA treatment from 24 to 72 h. Quantification of ICAM-2 Western-Blot
was performed by densitometry, normalized with respect of α-tubulin.
Error bars indicate mean ± s.e.m., n=5. t-test control vs IC2 siRNA *p<0.05,
**p<0.01. B- Analysis by Western-blot of N-Cad level after N-Cad siRNA
treatment from 24 to 96 h. Quantification of N-Cad Western-Blot was
performed by densitometry, normalized with respect of α-tubulin. Error
bars indicate mean ± s.e.m., n=5. t-test control vs N-Cad siRNA *p<0.05,
**p<0.01,***p<0.001).
Additional file 3: Figure S3. Distribution of VEC and PECAM-1 in
HUVEC treated with ICAM-2 siRNA. VEC was visualized using mAb
Cl55-7H1 followed by anti-mouse AlexaFluor 488 (Green) and PECAM-1
was visualised using mAb P2B1 anti-human PECAM-1 prelabelled with
the Zenon
® mouse IgG1 555 kit (Red). Bar = 25 μm.
Additional file 4: Figure S4. Endothelial characteristics of the
endothelioma cell lines. A- Phase contrast image of WT Pmt, KOIC2
Pmt cell lines, showing that IC2 Pmt as well as have lost the typical
cobblestone monolayer morphology and grow on top of each other
whilst WT Pmt cell line have a cobblestone structure Bar= 150 μm.
B- ICAM-2 over-expression restores tube formation on Matrigel. Cells
were plated onto 48 wells (25000 cells/well) pre-coated with reduced
growth factor Matrigel. Phase contrast pictures were taken 9 hours
post-seeding using digital camera model DP50-CU (Olympus) connected
to a Leitz labovert inverted microscope (Leica microsystems, objective
x10). Bar=200 μm. C- Representative FACs profile of ICAM-2 and endoglin
surface levels on IC2 neg, IC2 FL and HUVEC cells.
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